{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T17:40:55Z","timestamp":1792431655635,"version":"4.5.0"},"reference-count":18,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,5,6]],"date-time":"2022-05-06T00:00:00Z","timestamp":1651795200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:p>Epidermal nevus syndromes encompass a highly heterogeneous group of systemic disorders, characterized by epidermal nevi, and a spectrum of neuromuscular, ocular, and bone abnormalities. Cutaneous-skeletal hypophosphatemia syndrome (CSHS) constitutes a specific sub-entity in which elevated levels of fibroblast growth factor-23 cause hypophosphatemic rickets that are, to date, not amenable to causal therapy. Here, we report the first long-term follow-up of causal treatment with burosumab in a 3-year-old female patient with CSHS. 4 weeks after initiation of burosumab treatment, serum phosphate normalized to age-appropriate levels. Furthermore, long-term follow-up of 42 months revealed significant improvement of linear growth and gross physical functions, including respiratory insufficiency. Radiographic rickets severity as well as subjective bone pain were strongly reduced, and no side effects were observed over the course of treatment. In summary, we, here, report about a successful treatment of hypophosphatemic rickets in CSHS with burosumab over the time course of 42 months. In our patient, burosumab showed convincing efficacy and safety profile, without any loss of effect or increase of dose.<\/jats:p>","DOI":"10.3389\/fendo.2022.866831","type":"journal-article","created":{"date-parts":[[2022,5,6]],"date-time":"2022-05-06T07:37:12Z","timestamp":1651822632000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":20,"title":["A Case Report: First Long-Term Treatment With Burosumab in a Patient With Cutaneous-Skeletal Hypophosphatemia Syndrome"],"prefix":"10.3389","volume":"13","author":[{"given":"Lea Maria","family":"Merz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florian","family":"Buerger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niels","family":"Ziegelasch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Zenker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilse","family":"Wieland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tobias","family":"Lipek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tillmann","family":"Wallborn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Terliesner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Freerk","family":"Prenzel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuela","family":"Siekmeyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katalin","family":"Dittrich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,5,6]]},"reference":[{"key":"B1","unstructured":"The Group of Epidermal Nevus Syndromes Part IWell Defined Phenotypes - PubMed"},{"key":"B2","doi-asserted-by":"publisher","first-page":"43","DOI":"10.4161\/cc.23108","article-title":"Mosaic RASopathies","volume":"12","author":"Hafner","year":"2013","journal-title":"Cell Cycle"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-018-0905-7","article-title":"Burosumab: First Global Approval","volume":"78","author":"Lamb","year":"2018","journal-title":"Drugs"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.bonr.2021.101138","article-title":"Burosumab Treatment in a Child With Cutaneous Skeletal Hypophosphatemia Syndrome: A Case Report","volume":"15","author":"Khadora","year":"2021","journal-title":"Bone Rep"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1002\/jbmr.4233","article-title":"Burosumab for the Treatment of Tumor-Induced Osteomalacia","volume":"36","author":"Jan de Beur","year":"2021","journal-title":"J Bone Miner Res"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)30654-3.Burosumab","article-title":"Burosumab Versus Conventional Therapy in Children With X-Linked Hypophosphataemia: A Randomised, Active-Controlled, Open-Label, Phase 3 Trial","volume":"393","author":"Imel","year":"2019","journal-title":"Lancet"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1002\/jbmr.3377","article-title":"Validation of a Novel Scoring System for Changes in Skeletal Manifestations of Hypophosphatasia in Newborns, Infants, and Children: The Radiographic Global Impression of Change Scale","volume":"33","author":"Whyte","year":"2018","journal-title":"J Bone Miner Res"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2015.11.012","article-title":"Cutaneous Skeletal Hypophosphatemia Syndrome (CSHS) Is a Multilineage Somatic Mosaic RASopathy","volume":"75","author":"Lim","year":"2016","journal-title":"J Am Acad Dermatol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1007\/s00381-020-04770-9","article-title":"Neurocutaneous Melanocytosis (Melanosis)","volume":"36","author":"Ruggieri","year":"2020","journal-title":"Child\u2019s Nerv Syst"},{"key":"B10","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1093\/hmg\/ddt429","article-title":"Multilineage Somatic Activating Mutations in HRAS and NRAS Cause Mosaic Cutaneous and Skeletal Lesions, Elevated FGF23 and Hypophosphatemia","volume":"23","author":"Lim","year":"2014","journal-title":"Hum Mol Genet"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1111\/his.12672","article-title":"Bombesin Staining in Neuroendocrine Cell Hyperplasia of Infancy (NEHI) and Other Childhood Interstitial Lung Diseases (chILD)","volume":"67","author":"Yancheva","year":"2015","journal-title":"Histopathology"},{"key":"B12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1530\/EJE-09-0597","article-title":"Fibroblast Growth Factor 23 and its Role in Phosphate Homeostasis","volume":"162","author":"Ramon","year":"2010","journal-title":"Eur J Endocrinol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1172\/jci19081","article-title":"Targeted Ablation of Fgf23 Demonstrates an Essential Physiological Role of FGF23 in Phosphate and Vitamin D Metabolism","volume":"113","author":"Shimada","year":"2004","journal-title":"J Clin Invest"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1042\/BJ20041799","article-title":"Role of the Vitamin D Receptor in FGF23 Action on Phosphate Metabolism","volume":"390","author":"Inoue","year":"2005","journal-title":"Biochem J"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1210\/jcem-52-3-463","article-title":"X-Linked Hypophosphatemia: Effect of Calcitriol on Renal Handling of Phosphate, Serum Phosphate, and Bone Mineralization","volume":"52","author":"Costa","year":"1981","journal-title":"J Clin Endocrinol Metab"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1056\/nejm197209072871003","article-title":"Use of Phosphate and Vitamin D to Prevent Dwarfism and Rickets in X-Linked Hypophosphatemia","volume":"287","author":"Glorieux","year":"1972","journal-title":"N Engl J Med"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1714641","article-title":"Burosumab Therapy in Children With X-Linked Hypophosphatemia","volume":"378","author":"Carpenter","year":"2018","journal-title":"N Engl J Med"},{"key":"B18","first-page":"1","article-title":"Product Monograph, Crysvita, Burosumab, FGF23 Inhibitor, Kyowa Kirin Limited, Galabank Business Park","year":"2020"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2022.866831\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,6]],"date-time":"2022-05-06T07:37:16Z","timestamp":1651822636000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2022.866831\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,6]]},"references-count":18,"alternative-id":["10.3389\/fendo.2022.866831"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2022.866831","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,6]]},"article-number":"866831"}}